Business Context and Reporting Period
This Form 8-K, filed on October 1, 2013, reports events occurring on September 30, 2013, involving Intrexon Corporation (the Registrant). The filing details a strategic partnership with Oragenics, Inc. focused on the development and commercialization of genetically modified probiotics for treating diseases of the oral cavity, throat, sinus, and esophagus.
Key Financial Metrics and Transaction Details
The filing describes a material definitive agreement and associated financial transactions rather than periodic financial performance metrics. Key transaction values include:
- Private Placement: Intrexon purchased 1,300,000 shares of Oragenics common stock at $3.00 per share, generating gross proceeds of $3,900,000 for Oragenics.
- Technology Access Shares: Oragenics issued 1,348,000 shares of common stock to Intrexon as consideration for the collaboration agreement.
- Convertible Promissory Note: Oragenics issued a note to Intrexon in the principal amount of $1,956,000, maturing on December 31, 2013.
- Revenue Sharing: Oragenics agreed to pay Intrexon 10% of net sales from products developed under the agreement.
- Milestone Payments: Potential future payments to Intrexon include $2,000,000 for Phase II dosing, $5,000,000 for Phase III primary endpoint achievement, and $10,000,000 for first commercial sale or regulatory approval.
The filing text does not provide clear values for Intrexon's overall revenue, profit, cash flow, margins, or total debt as this is a current report on a specific event, not a periodic financial statement.
Material Changes and Agreements
On September 30, 2013, Intrexon entered into an Exclusive Channel Collaboration Agreement (ECC) and a Stock Purchase and Issuance Agreement (SPIA) with Oragenics. Under the ECC, Oragenics received an exclusive worldwide license to use Intrexon's proprietary technology for the specified field. Oragenics is responsible for funding development, clinical trials, and commercialization, while Intrexon handles technology discovery and cell-engineering. The SPIA includes a three-year standstill provision restricting Intrexon from seeking control or initiating acquisition activities regarding Oragenics.
Outlook, Risks, and Contingencies
Outlook and Milestones: Future financial returns for Intrexon are contingent upon Oragenics achieving specific clinical and commercial milestones. Payments may be made in cash or Oragenics stock, depending on Oragenics' option and specific contract terms regarding company sales.
Risks and Termination: Oragenics may voluntarily terminate the agreement with 90 days' written notice. Intrexon may terminate if Oragenics breaches the agreement or fails to pursue development of a "Superior Therapy." Upon termination, Oragenics may retain rights to products that are already approved, in regulatory review, or in clinical trials.
Contingencies: The Convertible Promissory Note requires shareholder approval prior to conversion. If Oragenics is sold before milestone payments are made, subsequent payments must be made in cash.
Investor Verification Checklist
- Verify the exact terms of the "Superior Therapy" definition in the ECC to understand Intrexon's termination rights.
- Confirm the status of shareholder approval required for the conversion of the $1,956,000 Convertible Promissory Note.
- Review the confidential portions of Exhibit 10.1 (ECC) to understand specific exceptions to the 10% net sales royalty.
- Assess Oragenics' current cash position and ability to fund the required development and clinical trials without additional dilution.
- Monitor the timeline for the first Phase II clinical trial dosing to trigger the initial $2,000,000 milestone payment.